VarmX was founded by Pieter Reitsma in 2016.

Who are VarmX's investors?

VarmX's investors include Sound Bioventures, Ysios Capital, BioGeneration Ventures, EIC, EQT Life Sciences, Inkef, UNIIQ, BGV and 1 more.

VarmX

Founded 2016 · 36 employees on LinkedIn · 14 known investors

Find your way into VarmX

587 people in our graph share verified history with the VarmX team — schools, employers, funds. One of them is your warm intro.

Teresa Chanunlockedknows John Glasspool · together at Johnson and Johnson (overlapped)

×6knows the team · via Massachusetts Institute of Technology- NEWDIGS

×2knows the team · via Johnson and Johnson

knows the team · via University of Staffordshire

knows the team · via Oxford Brookes University

knows the team · via Roivant Sciences

VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings. The company focuses on advancing coagulation therapy for patients taking this class of blood thinners.

Biotech Healthtech Medical Devices

Founders & leadership

VarmX was founded in 2016 by Pieter Reitsma.

Pieter ReitsmainFounder

John Glasspool in 𝕏Chief Executive OfficerVenture Partner at Agent Capital

Investors · 14

Sound Bioventures✓ verifiedMalmö

Ysios Capital✓ verifiedBarcelona · $5.4M – $21.6M

BioGeneration Ventures✓ verifiedNaarden

EIC✓ verifiedOrinda

EQT Life Sciences✓ verifiedLuxembourg · $11M – $66M

Inkef✓ verifiedAmsterdam

UNIIQThe Hague

BGVreportedSilicon Valley

Lundbeckfonden VenturesreportedCopenhagen

Also in the syndicate · 5

BioGeneration Ventures (BGV)European Innovation Council (EIC) FundInnovationQuarter (IQ)Libertatis Ergo Holding (LEH)Lundbeckfonden BioCapital

Funding

SEC filings, press & company announcements

Undisclosed amountSeries B2May 2023 · 3 sources
Sound Bioventures (lead), BioGeneration Ventures (BGV), EQT Life Sciences, European Innovation Council (EIC) Fund, Inkef, InnovationQuarter (IQ), Libertatis Ergo Holding (LEH), Lundbeckfonden BioCapital, Ysios Capital
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

VarmX enrols first participant in global Phase 3 EquilibriX-S trial evaluating VMX C001 in urgent surgery - BioSpacebiospace.com · Aug 2026

VarmX raises €30M for blood clotting triallabiotech.eu · May 2023

VarmX raises €30 million Series B2 financing – Ysios Capitalysioscapital.com · May 2023

VarmX Raises €30 Million Series B2 Financing for IND Approval and Preparations for Pivotal Trialbusinesswire.com · May 2023

VarmX Raises €32 Million in Series B Financing to Develop Innovative Reversal Agent for the Treatment and Prevention of Severe Bleeding in Patients on Oral Anticoagulantshmpgloballearningnetwork.com · Jul 2020

VarmX Raises € 12.5 Million to Develop Modified Blood Coagulation Factor X for Treating Severe Bleeding in Patients Using Anti-Coagulants - BioSpacebiospace.com · Jul 2018

Frequently asked questions

What does VarmX do?: VarmX develops VMX-C001, a therapeutic medicine for treating severe bleeding in patients on Factor Xa anticoagulants and for emergency surgery settings. The company focuses on advancing coagulation therapy for patients taking this class of blood thinners.
Who founded VarmX?: VarmX was founded by Pieter Reitsma in 2016.
Who are VarmX's investors?: VarmX's investors include Sound Bioventures, Ysios Capital, BioGeneration Ventures, EIC, EQT Life Sciences, Inkef, UNIIQ, BGV and 1 more.